Neuromed Receives Milestone Payment of $2 Million Under Collaboration and License Agreement with Merck & Co., Inc.



    VANCOUVER, BC and CONSHOHOCKEN, PA, March 14 /CNW/ - Neuromed
Pharmaceuticals, a biopharmaceutical company developing next-generation
chronic pain drugs, announced today that it has received a milestone payment
of $2 million under its collaboration and license agreement with Merck & Co.,
Inc.
    "Neuromed and Merck have built a productive partnership and we are very
pleased with the progress we are making through our alliance," said Dr.
Christopher Gallen, President & CEO of Neuromed. "N-type calcium channels are
an important target for pain. Merck's commitment to this program gives it the
highest chance to succeed in producing therapeutics for chronic pain and other
underserved markets. In 2006 we achieved our financial, discovery and clinical
objectives and we look forward to continuing our collaborative efforts in
2007."
    In March 2006, Neuromed and Merck entered into a research collaboration
and license agreement to research, develop and commercialize N-type calcium
channel blockers for the treatment of pain and other disorders.

    About Neuromed
    Neuromed is a privately held biopharmaceutical company developing a new
generation of chronic pain drugs with additional programs in epilepsy and
hypertension. Located in Vancouver, Canada and Conshohocken, USA, Neuromed is
the only company to advance an oral N-type calcium channel blocker for chronic
pain into clinical trials. N-type calcium channels are a key integration site
for pain signal transmission. For more information, visit
http://www.neuromed.com.





For further information:

For further information: Julie Jang, Manager, Communications, Neuromed
Pharmaceuticals, Phone: (604) 909-2547, Email: jjang@neuromed.com

Organization Profile

NEUROMED PHARMACEUTICALS LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890